Exact Sciences Q4 EPS Forecast Reduced by Leerink Partnrs

Exact Sciences Co. (NASDAQ:EXAS) – Equities researchers at Leerink Partnrs reduced their Q4 2024 earnings per share estimates for shares of Exact Sciences in a note issued to investors on Wednesday, November 6th. Leerink Partnrs analyst P. Souda now expects that the medical research company will post earnings of ($0.30) per share for the quarter, down from their previous forecast of ($0.04). The consensus estimate for Exact Sciences’ current full-year earnings is ($0.87) per share. Leerink Partnrs also issued estimates for Exact Sciences’ Q1 2025 earnings at ($0.10) EPS, Q2 2025 earnings at $0.02 EPS, Q3 2025 earnings at $0.06 EPS, FY2025 earnings at $0.12 EPS and FY2026 earnings at $0.61 EPS.

Other analysts also recently issued research reports about the company. Canaccord Genuity Group dropped their price target on Exact Sciences from $95.00 to $75.00 and set a “buy” rating on the stock in a research note on Wednesday. Sanford C. Bernstein increased their price target on shares of Exact Sciences from $75.00 to $90.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Stifel Nicolaus reduced their price target on shares of Exact Sciences from $82.00 to $67.00 and set a “buy” rating for the company in a research report on Wednesday. Citigroup dropped their price objective on shares of Exact Sciences from $80.00 to $75.00 and set a “buy” rating on the stock in a report on Wednesday. Finally, Jefferies Financial Group raised their target price on shares of Exact Sciences from $84.00 to $85.00 and gave the stock a “buy” rating in a report on Wednesday. One equities research analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Exact Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $75.06.

Exact Sciences Price Performance

Shares of EXAS opened at $51.48 on Friday. The firm has a market capitalization of $9.53 billion, a PE ratio of -44.00 and a beta of 1.27. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.12 and a quick ratio of 1.98. The company’s fifty day moving average price is $66.76 and its 200-day moving average price is $56.51. Exact Sciences has a 1-year low of $40.62 and a 1-year high of $79.62.

Exact Sciences (NASDAQ:EXAS) last posted its quarterly earnings data on Tuesday, November 5th. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.01). The company had revenue of $708.66 million for the quarter, compared to analyst estimates of $716.80 million. Exact Sciences had a negative net margin of 7.95% and a negative return on equity of 6.17%. The business’s quarterly revenue was up 12.8% compared to the same quarter last year.

Insider Buying and Selling

In other Exact Sciences news, EVP Brian Baranick sold 929 shares of the stock in a transaction on Tuesday, October 8th. The shares were sold at an average price of $70.00, for a total transaction of $65,030.00. Following the transaction, the executive vice president now directly owns 12,758 shares of the company’s stock, valued at $893,060. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.36% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Chicago Partners Investment Group LLC raised its holdings in shares of Exact Sciences by 1.7% during the third quarter. Chicago Partners Investment Group LLC now owns 9,261 shares of the medical research company’s stock valued at $651,000 after acquiring an additional 158 shares during the last quarter. Daiwa Securities Group Inc. raised its stake in Exact Sciences by 1.7% in the 1st quarter. Daiwa Securities Group Inc. now owns 11,947 shares of the medical research company’s stock valued at $825,000 after purchasing an additional 200 shares during the last quarter. Amalgamated Bank lifted its holdings in Exact Sciences by 2.7% in the 2nd quarter. Amalgamated Bank now owns 10,937 shares of the medical research company’s stock valued at $462,000 after purchasing an additional 284 shares in the last quarter. Midwest Professional Planners LTD. boosted its stake in Exact Sciences by 12.3% during the 1st quarter. Midwest Professional Planners LTD. now owns 3,088 shares of the medical research company’s stock worth $213,000 after purchasing an additional 339 shares during the last quarter. Finally, EverSource Wealth Advisors LLC grew its holdings in shares of Exact Sciences by 92.4% during the first quarter. EverSource Wealth Advisors LLC now owns 708 shares of the medical research company’s stock worth $49,000 after buying an additional 340 shares in the last quarter. 88.82% of the stock is owned by hedge funds and other institutional investors.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.